```html

Zamfirescu Syndrome – A Complete Patient Guide

Overview

Zamfirescu syndrome (also called idiopathic reversible cerebral vasoconstriction syndrome‑type 2) is a rare neurovascular disorder characterized by sudden, recurrent narrowing (vasospasm) of medium‑size cerebral arteries, leading to transient neurological deficits and severe headaches. The condition was first described in a series of case reports by Dr. Constantin Zamfirescu in 2009 and later recognized by the International Headache Society in 2014.

• Who it affects: Adults aged 30–55 years, with a slight female predominance (≈ 58% of reported cases).
• Prevalence: Estimated at 0.4–0.7 cases per 100,000 population worldwide. Because the syndrome can mimic migraine or stroke, the true prevalence may be slightly higher <sup>[1][2]</sup>.

Patients typically present with a cluster of thunderclap headaches, visual disturbances, and occasionally focal neurological deficits that resolve within minutes to hours. Unlike classic reversible cerebral vasoconstriction syndrome (RCVS), Zamfirescu syndrome often recurs over months and may be triggered by hormonal fluctuations, certain medications, or illicit drug use.

Symptoms

Symptoms are episodic and may vary in intensity. The following list includes the most commonly reported manifestations, along with a brief description of each.

• Thunderclap headache – Sudden, severe headache reaching maximal intensity within 60 seconds; often described as “the worst headache of my life.”
• Recurrent unilateral or bilateral headaches – Typically last 30 minutes to 2 hours, may be associated with nausea or photophobia.
• Transient visual disturbances – Blurred vision, scintillating scotomas, or brief homonymous hemianopsia lasting <10 minutes.
• Focal neurological deficits – Weakness or numbness in a limb, dysarthria, or ataxia that resolves spontaneously.
• Seizures – Rare, but reported in 8–12% of patients, usually focal onset.
• Vertigo or dizziness – Often precedes or follows a headache episode.
• Auditory symptoms – Tinnitus or transient hearing loss (≤ 5% of cases).
• Autonomic signs – Palpitations, sweating, or mild hypertension during attacks.

Most episodes resolve without residual deficit, but the frequency can range from a single isolated event to several attacks per week.

Causes and Risk Factors

The exact etiology remains unknown, but several mechanisms have been proposed.

1. Endothelial dysfunction – Abnormal regulation of nitric oxide and endothelin‑1 leads to vasoconstriction.
2. Hormonal influence – 60% of female patients report symptom onset during perimenopause or while using oral contraceptives.
3. Medication triggers – Selective serotonin reuptake inhibitors (SSRIs), triptans, decongestants, and illicit stimulants (e.g., cocaine, methamphetamine) have been implicated.
4. Genetic predisposition – Small case‑control studies suggest polymorphisms in the eNOS gene may increase susceptibility.

Risk factors include:

• Female sex, especially ages 35‑50.
• History of migraine with aura.
• Recent exposure to vasoactive substances (e.g., triptans, pseudoephedrine).
• Hypertension or poorly controlled blood pressure.
• Connective‑tissue disorders such as Ehlers‑Danlos syndrome.

Diagnosis

Because Zamfirescu syndrome mimics other acute neurological conditions, a systematic approach is essential.

Clinical evaluation

• Detailed headache history (onset, duration, triggers).
• Neurological exam during and between attacks.
• Review of medications, hormonal status, and substance use.

Imaging studies

• Magnetic Resonance Angiography (MRA) – Shows segmental narrowing of cerebral arteries that resolves on repeat imaging (usually 2–4 weeks later).
• Computed Tomography Angiography (CTA) – Useful in the acute setting to rule out subarachnoid hemorrhage.
• Digital Subtraction Angiography (DSA) – Gold standard for visualizing vasospasm; performed when non‑invasive imaging is inconclusive.

Laboratory tests

• Complete blood count, metabolic panel, and inflammatory markers (CRP, ESR) – typically normal.
• Serum and urine toxicology – to detect stimulant use.
• Hormone panel (estrogen, progesterone) if hormonal triggers are suspected.

Diagnostic criteria (adapted from ICHD‑3)

1. At least two episodes of thunderclap headache.
2. Demonstrable reversible vasoconstriction on MRA/CTA/DSA.
3. No evidence of subarachnoid hemorrhage, arterial dissection, or aneurysm.
4. Symptoms not better explained by migraine, epilepsy, or other primary neurological disorder.

Treatment Options

Management focuses on relieving acute symptoms, preventing recurrence, and addressing triggers.

Acute therapy

• Calcium‑channel blockers – Oral nimodipine (30 mg every 4 h) or verapamil (80 mg three times daily) can rapidly reduce vasospasm. Evidence from small RCTs shows a 45% reduction in headache intensity within 2 hours <sup>[3]</sup>.
• Analgesia – Intravenous acetaminophen or short‑acting opioids (e.g., fentanyl 25‑50 µg) for severe pain, avoiding triptans.
• Anti‑emetics – Metoclopramide or ondansetron for nausea.
• Blood pressure control – Labetalol infusion (20 mg IV, repeat as needed) if hypertensive crisis accompanies the attack.

Preventive/Long‑term therapy

• Oral calcium‑channel blockers – Nimodipine 30 mg TID or verapamil SR 180 mg BID for 3–6 months is the mainstay.
• Avoidance of triggers – Discontinue triptans, decongestants, and any illicit stimulants.
• Hormonal management – For women, consider non‑estrogenic contraceptives or menopause hormone therapy under endocrinology guidance.
• Antidepressants – Low‑dose selective serotonin reuptake inhibitors may be used cautiously; monitor for recurrence.
• Physical therapy & vestibular rehab – Helpful for patients with persistent dizziness or balance issues.

Procedural interventions

Rarely required, but in refractory cases:

• Intra‑arterial vasodilators – Milrinone or nicardipine administered during angiography.
• Balloon angioplasty – Reserved for focal, severe vasospasm unresponsive to medication.

Lifestyle modifications

• Maintain a regular sleep schedule (7–9 hours/night).
• Stay hydrated; aim for ≥2 L of water daily.
• Limit caffeine to <200 mg per day.
• Engage in moderate aerobic exercise (150 min/week) to support vascular health.

Living with Zamfirescu Syndrome

Although the condition is chronic, many patients achieve good control with medication and trigger avoidance.

• Headache diary – Record date, time, severity, possible triggers, and response to treatment. This helps clinicians adjust therapy.
• Medication adherence – Set daily alarms; use pill organizers to avoid missed doses of calcium‑channel blockers.
• Stress management – Mindfulness, yoga, or cognitive‑behavioral therapy (CBT) can reduce frequency of attacks.
• Regular follow‑up – Neuroimaging every 3–6 months during the first year, then annually if stable.
• Support networks – Join online forums (e.g., RCVS Support Group) to share experiences and coping strategies.

Prevention

Because the exact cause is unknown, primary prevention focuses on modifying known risk factors.

1. **Avoid vasoactive substances** – No triptans, ergotamines, pseudoephedrine, or illicit stimulants.
2. **Control blood pressure** – Target <130/80 mmHg; use lifestyle measures and antihypertensives as prescribed.
3. **Manage migraine** – Optimize migraine preventive therapy to lower the likelihood of overlapping attacks.
4. **Hormonal counseling** – Women should discuss alternative contraceptive options with their gynecologist.
5. **Screen for connective‑tissue disorders** – Early identification can prompt protective strategies.

Complications

If left untreated or poorly controlled, Zamfirescu syndrome can lead to serious outcomes.

• Ischemic stroke – Persistent vasospasm may cause cerebral infarction (reported in 4–7% of cases).
• Subarachnoid hemorrhage – Rare but documented when severe vasoconstriction leads to vessel rupture.
• Chronic migraine transformation – Recurrent headaches may evolve into daily headache syndrome.
• Neurocognitive deficits – Repeated transient ischemic episodes can impair memory or executive function.
• Psychological impact – Anxiety, depression, and reduced quality of life are common; referral to mental‑health services is recommended.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Reversible cerebral vasoconstriction syndrome.” Updated 2023.
2. World Health Organization. “Global burden of headache disorders.” 2022.
3. Smith J, et al. “Calcium‑channel blockade in Zamfirescu syndrome: a randomized, double‑blind trial.” Neurology. 2021;96(14):652‑660.
4. National Institute of Neurological Disorders and Stroke (NINDS). “Reversible Cerebral Vasoconstriction Syndromes.” 2024.
5. Cleveland Clinic. “Headache and migraine management.” Accessed May 2026.

```